Viewing Study NCT00290277



Ignite Creation Date: 2024-05-05 @ 4:40 PM
Last Modification Date: 2024-10-26 @ 9:22 AM
Study NCT ID: NCT00290277
Status: COMPLETED
Last Update Posted: 2016-09-28
First Post: 2006-02-10

Brief Title: Evaluate the Immunogenicity Safety of GSK Biologicals HPV Vaccine in Female Subjects Aged 10-14 Years
Sponsor: GlaxoSmithKline
Organization: GlaxoSmithKline

Study Overview

Official Title: Evaluate the Immunogenicity Safety of GSK Biologicals HPV-1618 L1AS04 Vaccine Administered Intramuscularly According to a 016 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs
Status: COMPLETED
Status Verified Date: 2016-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Human papillomavirus infection has clearly been recognized as the cause of cervical cancer Indeed the infection of the cervix by certain oncogenic types of HPV if not cleared can lead over time to cervical cancer in women This study will evaluate the immunogenicity and the safety of the HPV vaccine in female subjects aged 10 - 14 years in Korea
Detailed Description: Study participants will receive either HPV or hepatitis A vaccine study duration will last for 7 months and involve a total of 4 visits

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None